Pre-injection of exosomes can significantly suppress ovarian cancer growth by activating the immune system in mice
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-03951-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Yuanyuan Wang und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Hu…. Hauptthemen laut MEDLINE: Exosomes, Ovarian Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
As a type of "cold tumor" with limited immune cell infiltration, ovarian cancer has historically shown limited efficacy in immunotherapy. In this study, we report that exosomes from ovarian cancer can specifically target omentum which is the predilection site for ovarian cancer to metastasize and combat subsequently implanted tumor. Furthermore, we found a substantial increase in the proportion of CD3 + T cells, particularly CD8 + T cells, within the omental tissue where exosomes homed. This increase was accompanied by a significant enhancement in granzyme B levels within CD8 + T cells. Additionally, there was a notable elevation in the concentration of interferon-gamma (IFN-γ) in peripheral blood. In vitro results indicated that exosomes could be internalized by dendritic cells (DCs), promote DC differentiation, and subsequently induce the production of granzyme B and IFN-γ in T cells. Surprisingly, we also observed high expression of programmed death ligand 1 (PD-L1) in the omentum. Therefore, we discovered whether combining PD-L1 blockade led to further tumor regression. However, although the combination group showed complete tumor regression, this difference did not reach statistical significance. But in general, we emphasize that in the case of pre-injection, exosomes have great potential to combat the famous "cold tumor", ovarian cancer, via targeting omentum and activating anti-tumor immunity, offering a novel avenue for overcoming ovarian cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
- Department of Obstetrics and Gynecology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. wangzanhong@126.…
- Department of Obstetrics and Gynecology, National Clinical Research Center for Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. hanzq2003@1…
- Department of Obstetrics and Gynecology, Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Tongji Shanxi Hospital, Third Hospital of Shanxi Medical University, Taiyuan, 030032, Shanxi, China. hanzq2003@126.co…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Wang, Y., Zhang, C., Zeng, H., Wang, L., Wang, Z., & Han, Z. (2025). Pre-injection of exosomes can significantly suppress ovarian cancer growth by activating the immune system in mice. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-03951-2
Vancouver
Wang Y, Zhang C, Zeng H, Wang L, Wang Z, Han Z. Pre-injection of exosomes can significantly suppress ovarian cancer growth by activating the immune system in mice. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-03951-2
BibTeX
@article{Wang2025,
author = {Wang, Yuanyuan and Zhang, Changyi and Zeng, Huimin and Wang, Liangliang and Wang, Zanhong and Han, Zhiqiang},
title = {Pre-injection of exosomes can significantly suppress ovarian cancer growth by activating the immune system in mice},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-03951-2}
}
EUVIMED